BusinessPets
0
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion - Fierce Pharma
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022
Comments